Home / Stocks / Bafna Pharmaceuticals Ltd
BAFNAPH Updated about 5 hours ago

Bafna Pharmaceuticals Ltd Share Price

NSE closing price and which mutual funds hold this stock

Daily NSE closing prices — this stock isn't in the live-tracked universe yet.

NSE Close — 19 Nov 2026

₹479.5

Change

+9.1 (1.93%)

Open

₹469.0

Prev. Close

₹470.4

Day High

₹479.5

Day Low

₹469.0

Volume Analysis

Traded

9,007

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (4)

  • •Low return on equity (-6.18%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (47/100)
  • •Low operating margin (2.9%)

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹493.5 ₹486.5 ₹483.0 ₹476.0 ₹472.5 ₹465.5 ₹462.0
Fibonacci ₹486.5 ₹482.49 ₹480.01 ₹476.0 ₹471.99 ₹469.51 ₹465.5
Camarilla ₹482.39 ₹481.43 ₹480.46 ₹476.0 ₹478.54 ₹477.58 ₹476.61

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+223.13%

1 Week

-2.51%

1 Month

+3.98%

3 Months

+97.77%

6 Months

+255.11%

1 Year

+186.97%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-46.86%

Net margin -57.14% × asset turnover 0.59x × equity multiplier 1.39x

Company Overview

Sector

Healthcare

Market Cap

₹1,121 Cr

ROE

-6.18%

Book Value

₹216.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Bafna Pharmaceuticals Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 47/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-6.18%); promoter holding is falling. FII holding has been rising.

TopFund Score — Fundamentals Quality

47/100 — Weak

Data confidence: 72/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

0

Valuation

50

Cash Flow

33

Corporate Governance

43

Momentum

93

Institutional Ownership

65

Business Quality

22

Risk & Volatility

68

Liquidity

0

From Screener.in

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Debtor days have improved from 151 to 51.8 days.
  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of -15.2% over past five years.
  • −Company has a low return on equity of -63.9% over last 3 years.
  • −Working capital days have increased from -77.3 days to 90.4 days

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

We herewith enclose the Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter & Half Year ended September 30, 2026 as …

Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2018 Sep 2018 Jun 2019 Sep 2019
Sales + 12 9 7 12
Expenses + 14 9 10 12
Operating Profit -2 0 -3 0
OPM % -15.23% 2.04% -41.75% -3.28%
Other Income + 0 0 0 1
Interest 1 1 0 0
Depreciation 1 1 1 1
Profit before tax -4 -1 -4 -1
Tax % -1.12% 4.1% -42.59% 7.27%
Net Profit + -4 -1 -2 -1
EPS in Rs -1 -1 -1 -2
Raw PDF — — — —
YoY Sales growth — — -43 31

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Sales + 129 175 185 97 85 65 46 44 42
Expenses + 110 153 162 114 85 71 81 57 41
Operating Profit 19 22 23 -18 1 -6 -35 -13 1
OPM % 15.0% 13.0% 12.0% -18.0% 0.6% -9.0% -77.0% -30.0% 2.9%
Other Income + 1 3 2 43 2 1 31 1 -22
Interest 8 12 13 13 13 11 7 2 0
Depreciation 6 8 9 6 5 4 4 3 3
Profit before tax 5 5 2 6 -15 -20 -15 -17 -24
Tax % 64.0% 27.0% 42.0% -2.0% -1.0% -4.0% 15.0% 6.0% 0.0%
Net Profit + 2 4 1 6 -15 -19 -17 -18 -24
EPS in Rs 1 2 1 3 -8 -10 -7 -8 -105
Dividend Payout % 0.0% 28.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sales growth — 36 5 -48 -12 -24 -30 -4 -3

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Reserves 45 49 50 53 39 24 14 -5 49
Borrowings + 85 100 108 69 80 82 47 46 3
Other Liabilities + 70 93 59 59 54 53 54 54 17
Total Liabilities 219 261 236 200 193 178 138 119 71
Fixed Assets + 76 73 69 55 53 49 45 37 35
CWIP 0 0 0 0 0 0 0 0 0
Investments 0 0 0 17 17 17 0 0 0
Other Assets + 143 188 167 128 123 113 93 82 36
Total Assets 219 261 236 200 193 178 138 119 71
Equity Capital 18 19 19 19 19 19 24 24 2

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Cash from Operating Activity + 29 37 2 11 1 -1 -7 -2 -34
Cash from Investing Activity + -38 -6 -7 60 0 -5 38 15 33
Cash from Financing Activity + -1 -12 -13 -71 -1 6 -31 -14 7
Net Cash Flow -9 19 -18 0 0 0 0 0 6
Free Cash Flow -1 34 0 44 -1 -1 40 3 -36
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 161 167 9 -73 175 16 20 14 -2,812

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 88.42% → 75.0%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 11.57% 11.7% 11.71% 11.7% 11.7% 16.47% 15.66% 15.66% 15.66% 15.66% 15.66% 15.66%
Promoters 88.42% 88.29% 88.29% 88.29% 88.29% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0%
FII 0.0% 0.0% 0.0% 0.0% 0.0% 8.53% 9.34% 9.34% 9.34% 9.34% 9.34% 9.34%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Bafna Pharmaceuticals Ltd (this stock) 1,121 — 2.19 -6.18%
Gpt Healthcare Limited 1,136 27.3 — 28.5%
Sigachi Industries Ltd 1,088 41.3 2.02 5.78%
3b Blackbio Dx Ltd. 1,157 19.7 3.33 19.8%
Laxmi Dental Limited 1,076 29.7 4.05 14.8%
Lincoln Pharma Ltd 1,032 10.6 1.27 12.0%
Gujarat Kidney N Sup Sp L 1,269 66.8 4.82 11.1%

Which Mutual Funds Hold Bafna Pharmaceuticals Ltd?

Frequently Asked Questions about Bafna Pharmaceuticals Ltd

Community Sentiment

What are other investors saying about Bafna Pharmaceuticals Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.